Buscar
Centessa Pharmaceuticals PLC
CNTAAñadir a la lista de seguimiento
40.500USD
0.0000.00%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
6.27BCap. mercado
PérdidaP/E TTM
Más Datos de Centessa Pharmaceuticals PLC Compañía
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Información de Centessa Pharmaceuticals PLC
Símbolo de cotizaciónCNTA
Nombre de la empresaCentessa Pharmaceuticals PLC
Fecha de salida a bolsaMay 28, 2021
Director ejecutivoSaha (Saurabh)
Número de empleados77
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 28
Dirección3rd Floor
CiudadALTRINCHAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalWA14 2DT
Teléfono447391789784
Sitio Webhttps://www.centessa.com/
Símbolo de cotizaciónCNTA
Fecha de salida a bolsaMay 28, 2021
Director ejecutivoSaha (Saurabh)
Ejecutivos de Centessa Pharmaceuticals PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
462.58K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
91.08K
+50.41%
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
3.89K
-1882.61%
Mr. Iqbal Hussain
Mr. Iqbal Hussain
General Counsel and Chief Compliance Officer, Company Secretary
General Counsel and Chief Compliance Officer, Company Secretary
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Francesco de Rubertis, Ph.D.
Dr. Francesco de Rubertis, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Brett I. W. Zbar, M.D.
Dr. Brett I. W. Zbar, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Carol Stuckley
Ms. Carol Stuckley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
462.58K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
91.08K
+50.41%
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
3.89K
-1882.61%
Mr. Iqbal Hussain
Mr. Iqbal Hussain
General Counsel and Chief Compliance Officer, Company Secretary
General Counsel and Chief Compliance Officer, Company Secretary
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Francesco de Rubertis, Ph.D.
Dr. Francesco de Rubertis, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Centessa Pharmaceuticals PLC?
Los cinco principales accionistas de Centessa Pharmaceuticals PLC son: Dr. Arjun Goyal, M.D.
¿Cuántas instituciones poseen acciones de Centessa Pharmaceuticals PLC (CNTA)?
A fecha de 2026Q1, 276 instituciones poseen acciones de Centessa Pharmaceuticals PLC, con un valor de mercado combinado de aproximadamente 150.25M, lo que representa el 97.10% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 12002120.00.
